Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Finerenone (Primary) ; Eplerenone
  • Indications Chronic heart failure; Left ventricular dysfunction
  • Focus Pharmacodynamics
  • Acronyms ARTS-HF
  • Sponsors Bayer

    • Most Recent Events

    • 10 May 2024 According to an Bayer media release, the company will present Kerendia data from its comprehensive clinical trial program in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in addition to data from FINEARTS-HF, at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC), taking place May 11-14, 2024 in Lisbon, Portugal.
    • 29 Apr 2016 Results (n=1066) published in the European Heart Journal
    • 14 Apr 2016 Results of ARTS-HF study in Japanese patients (n=72) published in the Circulation Journal.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top